Open AccessEvidence of Superiority of Sacubitril/Valsartan versus Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers in the Heart Failure with Reduced Ejection Fraction Patient's Journey
Author(s) -
Mauro Gori,
Emilia D’Elia,
Michele Senni
Publication year - 2021
Publication title -
cardiology plus
Language(s) - English
Resource type - Journals
eISSN - 2470-752X
pISSN - 2470-7511
DOI - 10.4103/2470-7511.312591
Subject(s) - tolerability , sacubitril , valsartan , sacubitril, valsartan , medicine , ejection fraction , heart failure , angiotensin receptor , cardiology , angiotensin converting enzyme , angiotensin ii , clinical trial , population , adverse effect , receptor , blood pressure , environmental health